lifestyle.ebusinessplanet.com

Author: GRAIL, Inc.

Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate

February 23, 2026
GRAIL Submits FDA Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

January 29, 2026
GRAIL to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 2, 2025